---
document_datetime: 2023-09-21 19:16:45
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/insuman-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: insuman-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 2.0497314
conversion_datetime: 2025-12-19 23:18:41.257176
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 May 2002 please refer to module 8B.

## Extension (change of source of active substance)

The company Hoechst Marion Roussel GmbH, Germany, submitted on 1 October 1997 to the EMEA an  application  to  obtain  a  Marketing  Authorisation  in  accordance  with  Annex  II  of  Commission Regulation (EC) No 542/95 of 10 March 1995 (part VI) for the medicinal product Insuman (human insulin).

- -The procedure for Insuman started on 24 October 1997.
- -The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  9  January 1998.
- -During the CPMP plenary meeting on 24 February 1998, the CPMP adopted the consolidated list  of  questions  for  Insuman  to  be  sent  to  the  company.  The  CPMP  consolidated  list  of questions was sent to the company on 25 February 1998.
- -The company submitted the responses to the consolidated list of questions on 8 April 1998.
- -The Rapporteur circulated the joint response assessment report on the company's responses to the list of questions to all CPMP Members on 25 May 1998.
- -The CPMP, during its meeting on 23 June 1998, discussed the recommendations presented by the Rapporteur, considering the responses provided by the company satisfactory.
- -The  CPMP  during  its  meeting  of  23-25  June  1998  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Insuman on 24 June 1998.
- -The Commission Decision for this extension was issued on 11 November 1998.

## Subsequent extensions

## Additional route of administration for Insuman Rapid: intravenous use

On  20  January  2000,  the  CPMP  issued  a  positive  opinion  for  Insuman  Rapid,  intravenous  use. Insuman Rapid administered intravenously is suitable for the treatment of hyperglycaemic coma and ketoacidosis,  as  well  as  for  achieving  pre-,  intra-  and  post-operative  stabilisation  in  patients  with diabetes mellitus. In addition the Part II of the dossier was updated to take into account the change in Insuman Rapid from the previous source (insulin HGT) to the new source of active ingredient (insulin HR1799).  Minor  changes  to  the  manufacturing  process  were  also  introduced.  The  Commission Decision for this extension was issued on 01 August 2000.

## Variations

All variations and notifications agreed upon  after granting the Marketing  Authorisation are summarised in the table below.

<div style=\"page-break-after: always\"></div>

| Scope                                                                                                                                                                                                           | Type of modification 1   | Submission date   | Notification/ Opinion Date   | CPMP opinion    | Change in Comm. Decision   | Date of Comm. Decision   |    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-------------------|------------------------------|-----------------|----------------------------|--------------------------|----|
| Additional pack size: 4 cartridges for Insuman (Rapid, Basal, Comb 15, Comb 25, Comb 50)                                                                                                                        | II                       | 27.11.98          | 16.12.99                     | Change accepted | Annex I, III               | 18.02.99                 |  1 |
| Additional pack size: 10 cartridges for Insuman (Rapid, Basal, Comb 15, Comb 25, Comb 50)                                                                                                                       | II                       | 27.11.98          | 16.12.99                     | Change accepted | Annex I, III               | 18.02.99                 |  2 |
| Additional presentations: Insuman in a pre-filled disposable injection pen: Insuman OptiSet (Rapid, Basal, Comb 15, Comb 25, Com 50)                                                                            | II                       | 12.07.99          | 18.11.99                     | Change accepted | Annex I, III               | 20.03.00                 |  4 |
| Update of Part II of the dossier to take into account the change from the previous source (insulin HGT) to the new source of active ingredient (insulin HR1799) and additional minor changes to the             | II                       | 10.08.99          | 20.01.00                     | Change accepted | -                          | 22.02.00                 |  5 |
| Change to the specifications of the active substance                                                                                                                                                            | II                       | 13.10.99          | 13.04.00                     | Change accepted | -                          | 28.04.00                 |  6 |
| Change in test procedure of active substance                                                                                                                                                                    | I/II                     | 05.07.00          | 19.10.00                     | Change accepted | -                          | 15.11.00                 |  7 |
| Change(s) to the manufacturing process for the active substance                                                                                                                                                 | II                       | 05.08.00          | 19.10.00                     | Change accepted | -                          | 15.11.00                 |  8 |
| Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                | II                       | 16.08.00          | 14.12.00                     | Change accepted | I, IIIA, IIIB              | 14.06.01                 |  9 |
| Change in the name and/or address of the marketing authorisation holder (from Hoechst Marion Roussel Deutschland GmbH to Aventis Pharma Deutschland GmbH) Change following modification(s) of the manufacturing | I                        | 14.08.00          | 21.12.00                     | Change accepted | I, II, IIIA, IIIB          | -                        | 10 |
| Update of or change(s) to the pharmaceutical documentation                                                                                                                                                      | II                       | 01.12.00          | 26.04.01                     | Change accepted | -                          | 04.05.01                 | 11 |
| Change in specification of medicinal product                                                                                                                                                                    | I                        | 08.10.01          | 12.12.01                     | Change accepted | -                          | -                        | 12 |
| Renewal of the Marketing Authorisation                                                                                                                                                                          | R                        | 08.10.01          | 13.12.01                     | Accepted        | I, II, IIIA,               | 22.03.02                 | 13 |
| Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                  | II                       | 26.11.01          | 25.04.02                     | Change accepted | IIIB -                     | 30.04.02                 | 14 |

1 T: Transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of  7 November 1996. I, II, I/II: In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (type I variation); II refers to a major variation (type II variation); I / II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation.